IceCure Medical (ICCM) expands 2024 employee share incentive reserve

Rhea-AI Filing Summary

IceCure Medical Ltd. reports that its board of directors approved an increase in the ordinary shares reserved for its 2024 Employee Equity Incentive Plan. The reserve rose by 2,500,000 ordinary shares, from 112,667 to 2,612,667 ordinary shares available for future equity awards to employees.

Filing Explained

The reserve now permits up to 2,612,667 plan shares, but the filing does not disclose a completed issuance affecting current holders.

As a Form 6-K interim report, the filing says IceCure Medical’s board approved on August 11, 2026 an increase in shares reserved under its 2024 Employee Equity Incentive Plan from 112,667 to 2,612,667, creating additional capacity for plan issuance rather than documenting a completed issuance.

The filing reports a reserve authorization, not an issuance of shares; if shares are later issued, the resulting increase in total shares could reduce existing holders’ percentage ownership.

The report is incorporated by reference into the specified F-3 and S-8 registration statements, adding this reserve disclosure to those registration-statement records.

Key Figures

Increase in plan reserve: 2,500,000 ordinary shares Previous plan reserve: 112,667 ordinary shares New total plan reserve: 2,612,667 ordinary shares +1 more

4 metrics

Increase in plan reserve 2,500,000 ordinary shares Additional ordinary shares reserved under the 2024 Employee Equity Incentive Plan approved on August 11, 2026

Previous plan reserve 112,667 ordinary shares Ordinary shares previously reserved under the 2024 Employee Equity Incentive Plan before the increase

New total plan reserve 2,612,667 ordinary shares Total ordinary shares now reserved under the 2024 Employee Equity Incentive Plan after the increase

Report date August 11, 2026 Date on which the board of directors approved the increase in the share reserve

Key Terms

Foreign Private Issuer, Form 6-K, Employee Equity Incentive Plan, incorporated by reference, +2 more

6 terms

Foreign Private Issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Employee Equity Incentive Plan financial

"2024 Employee Equity Incentive Plan by 2,500,000"

incorporated by reference regulatory

"This Report ... is incorporated by reference into the Company’s Registration Statements"

Form F-3 regulatory

"Registration Statements on Form F-3 (File Nos. 333-297030..."

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

Form S-8 regulatory

"and Form S-8 (333-270982, 333-264578, 333-262620..."

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

FAQ

What change did IceCure Medical (ICCM) make to its 2024 Employee Equity Incentive Plan?

IceCure Medical’s board approved an increase in shares reserved under its 2024 Employee Equity Incentive Plan. The pool rose by 2,500,000 ordinary shares, expanding from 112,667 to a total of 2,612,667 ordinary shares available for future grants.

How many additional shares did IceCure Medical (ICCM) reserve for employee equity awards?

The company reserved an additional 2,500,000 ordinary shares for its 2024 Employee Equity Incentive Plan. This board-approved increase substantially enlarges the pool of shares that can be granted to employees as equity compensation going forward.

What is the total number of shares now reserved under IceCure Medical’s (ICCM) 2024 plan?

After the change, a total of 2,612,667 ordinary shares are reserved under the 2024 Employee Equity Incentive Plan. This figure reflects the prior 112,667 reserved shares plus the newly approved 2,500,000 share increase by the board.

When did IceCure Medical’s (ICCM) board approve the increase in equity plan shares?

The board approved the increase in reserved shares on August 11, 2026. This decision expanded the 2024 Employee Equity Incentive Plan’s share pool from 112,667 to 2,612,667 ordinary shares for potential future employee grants.

How is this IceCure Medical (ICCM) share reserve change linked to its U.S. registrations?

The report describing the share reserve increase is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements. This means those registrations now include this updated equity plan share information by reference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/14/2026 - 04:18 PM Accepted by SEC EDGAR 08/14/2026 - 04:10 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026 (Report No. 4)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On August 11, 2026, the Board of Directors of IceCure Medical Ltd. (the “Company”) approved an increase in the number of ordinary shares, no par value per share, of the Company reserved for issuance under the Company’s 2024 Employee Equity Incentive Plan by 2,500,000 from 112,667 to 2,612,667 ordinary shares.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: August 14, 2026	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2